LV11175B - Novel sulfonylaminopyrymidine - Google Patents

Novel sulfonylaminopyrymidine Download PDF

Info

Publication number
LV11175B
LV11175B LVP-94-131A LV940131A LV11175B LV 11175 B LV11175 B LV 11175B LV 940131 A LV940131 A LV 940131A LV 11175 B LV11175 B LV 11175B
Authority
LV
Latvia
Prior art keywords
pyrimidin
methoxyphenoxy
yloxy
chloro
tert
Prior art date
Application number
LVP-94-131A
Other languages
English (en)
Latvian (lv)
Other versions
LV11175A (lv
Inventor
Volker Breu
Kaspar Burri
Jean-Marie Cassal
Martine Clozel
Georges Hirth
Bernd-Michael Loeffler
Marcel Mueller
Werner Neidhart
Henri Ramuz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of LV11175A publication Critical patent/LV11175A/xx
Publication of LV11175B publication Critical patent/LV11175B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LVP-94-131A 1993-06-28 1994-06-27 Novel sulfonylaminopyrymidine LV11175B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH192493 1993-06-28

Publications (2)

Publication Number Publication Date
LV11175A LV11175A (lv) 1996-04-20
LV11175B true LV11175B (en) 1996-06-20

Family

ID=4221780

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-94-131A LV11175B (en) 1993-06-28 1994-06-27 Novel sulfonylaminopyrymidine

Country Status (41)

Country Link
US (1) US5541186A (pt)
EP (1) EP0633259B1 (pt)
JP (1) JP2545200B2 (pt)
KR (1) KR100338905B1 (pt)
CN (1) CN1050839C (pt)
AT (1) ATE175669T1 (pt)
AU (1) AU678467B2 (pt)
BG (1) BG61691B1 (pt)
BR (2) BR9402558A (pt)
CA (1) CA2125730C (pt)
CO (1) CO4230230A1 (pt)
CZ (1) CZ287184B6 (pt)
DE (1) DE59407626D1 (pt)
DK (1) DK0633259T3 (pt)
EC (1) ECSP941111A (pt)
ES (1) ES2127850T3 (pt)
FI (1) FI112944B (pt)
GR (1) GR3029874T3 (pt)
HR (1) HRP940370B1 (pt)
HU (2) HUT67636A (pt)
IL (1) IL110089A (pt)
IS (1) IS4185A (pt)
LT (1) LT3723B (pt)
LV (1) LV11175B (pt)
MY (1) MY110871A (pt)
NO (1) NO306403B1 (pt)
NZ (1) NZ260842A (pt)
PE (1) PE56794A1 (pt)
PH (1) PH30688A (pt)
PL (2) PL177031B1 (pt)
RO (1) RO114325B1 (pt)
RU (1) RU2142457C1 (pt)
SG (1) SG43888A1 (pt)
SI (1) SI0633259T1 (pt)
SK (1) SK280736B6 (pt)
SV (1) SV1994000028A (pt)
TW (1) TW394761B (pt)
UA (1) UA40578C2 (pt)
UY (1) UY23797A1 (pt)
YU (1) YU40794A (pt)
ZA (1) ZA944434B (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
PL320263A1 (en) 1994-11-16 1997-09-15 Synaptic Pharma Corp Dihydropyrimidines and their application
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
TW313568B (pt) * 1994-12-20 1997-08-21 Hoffmann La Roche
ES2196090T3 (es) 1994-12-28 2003-12-16 Kowa Co Derivados pirimidinicos.
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
AU703892B2 (en) * 1995-09-06 1999-04-01 Kowa Co., Ltd. Pyrimidine derivatives
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
CZ260596A3 (en) * 1995-10-12 1997-12-17 Hoffmann La Roche Sulfonamide derivative, process of its preparation and pharmaceutical composition containing thereof
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
CN1102580C (zh) * 1995-12-20 2003-03-05 山之内制药株式会社 芳基乙烯基磺酰胺衍生物及其医药组合物
JP2001523218A (ja) 1996-02-20 2001-11-20 ブリストル―マイヤーズ・スクイブ・カンパニー ビフェニルイソキサゾール・スルホンアミドの製造法
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
AU4196697A (en) * 1996-09-16 1998-04-14 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
CA2315614C (en) * 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
WO2001081338A1 (en) * 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
CN1326841C (zh) 2000-09-25 2007-07-18 埃科特莱茵药品有限公司 具有内皮素拮抗剂活性的芳烷烃－磺胺类化合物
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
KR100374326B1 (ko) * 2000-11-29 2003-03-03 한국과학기술연구원 6-히드록시-1, 3-디옥신-4-온 고리를 가진인간면역결핍바이러스 프로테아제 억제 화합물 및 그의제조방법
NZ525614A (en) 2000-12-18 2005-03-24 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
WO2002083650A1 (en) * 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
AU2011218661B2 (en) * 2002-05-24 2012-07-05 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
EP2399903A1 (en) 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US7227035B2 (en) * 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
ES2286502T3 (es) * 2002-11-18 2007-12-01 Chemocentryx, Inc. Sulfonamidas de arilo.
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
RU2329255C2 (ru) 2002-12-02 2008-07-20 Актелион Фармасьютиклз Лтд Пиримидинсульфамиды и их использование в качестве антагонистов эндотелиальных рецепторов
DE102004027119A1 (de) 2003-06-06 2004-12-30 Schott Ag UV-Strahlung absorbierendes Glas mit geringer Absorption im sichtbaren Bereich, ein Verfahren zu seiner Herstellung sowie dessen Verwendung
BRPI0508461B8 (pt) * 2004-03-05 2021-05-25 Hoffmann La Roche diaminopirimidinas, seus usos, e composição farmacêutica
TWI380816B (zh) * 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
AU2005256442B2 (en) 2004-06-28 2009-02-12 F. Hoffmann-La Roche Ag Pyrimidine derivatives as 11beta-HSD1 inhibitors
KR100847203B1 (ko) * 2004-06-28 2008-07-17 에프. 호프만-라 로슈 아게 피리미딘 유도체
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
KR101025381B1 (ko) * 2005-09-01 2011-03-28 에프. 호프만-라 로슈 아게 Ｐ2ｘ3 및 ｐ2ｘ2/3 조정자로서의 다이아미노피리미딘
EP1924564B1 (en) * 2005-09-01 2016-11-09 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
EP1924566B1 (en) 2005-09-01 2016-01-13 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
CA2644784A1 (en) * 2006-03-13 2007-09-20 Jinling Chen Formulations of sitaxsentan sodium
WO2007106494A2 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of diastolic heart failure
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
EP3000487B8 (en) 2007-02-19 2022-06-15 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
NZ602909A (en) 2010-04-15 2015-01-30 Marinepolymer Tech Inc Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
JP6144254B2 (ja) 2011-04-15 2017-06-07 マリン ポリマー テクノロジーズ，インコーポレーテッド ポリ−ｎ−アセチルグルコサミンナノファイバを用いた疾患の治療
RU2604060C1 (ru) * 2015-10-06 2016-12-10 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Способ получения 2,5-дизамещенных 6-гидроксипиримидин-4(3н)-онов
SG11201808220VA (en) 2016-03-22 2018-10-30 Merck Sharp & Dohme Allosteric modulators of nicotinic acetylcholine receptors
RU2643356C2 (ru) * 2016-06-22 2018-02-01 федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Новое n-арилсульфамидное производное о-бензоиламинобензойной кислоты, обладающее анксиолитической, актопротекторной и антидепрессивной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3663598D1 (en) 1985-07-24 1989-06-29 Siemens Ag Nuclear-fuel assembly
TW270116B (pt) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (pt) * 1992-12-10 1996-10-01 Hoffmann La Roche

Also Published As

Publication number Publication date
YU40794A (sh) 1997-07-31
NO942428L (no) 1994-12-29
SG43888A1 (en) 1997-11-14
HU9401907D0 (en) 1994-09-28
NO306403B1 (no) 1999-11-01
BR9402558A (pt) 1995-03-28
EP0633259A1 (de) 1995-01-11
PE56794A1 (es) 1995-02-07
LT3723B (en) 1996-02-26
PH30688A (en) 1997-09-16
SK280736B6 (sk) 2000-07-11
HU211533A9 (en) 1995-12-28
IS4185A (is) 1994-12-29
US5541186A (en) 1996-07-30
IL110089A0 (en) 1994-10-07
BG98880A (bg) 1995-05-31
RU94022258A (ru) 1996-04-20
NO942428D0 (no) 1994-06-27
EP0633259B1 (de) 1999-01-13
HUT67636A (en) 1995-04-28
MY110871A (en) 1999-05-31
RU2142457C1 (ru) 1999-12-10
FI112944B (fi) 2004-02-13
CZ157394A3 (en) 1995-01-18
SV1994000028A (es) 1995-04-19
FI943084A (fi) 1994-12-29
ATE175669T1 (de) 1999-01-15
KR100338905B1 (ko) 2002-11-13
UY23797A1 (es) 1994-12-16
CZ287184B6 (en) 2000-10-11
ZA944434B (en) 1995-01-03
PL304007A1 (en) 1995-01-09
KR950000676A (ko) 1995-01-03
PL177031B1 (pl) 1999-09-30
AU6594894A (en) 1995-01-05
HRP940370A2 (en) 1996-12-31
ECSP941111A (es) 1994-11-16
CA2125730C (en) 2005-10-18
DE59407626D1 (de) 1999-02-25
JPH0717972A (ja) 1995-01-20
CN1106007A (zh) 1995-08-02
AU678467B2 (en) 1997-05-29
CN1050839C (zh) 2000-03-29
CA2125730A1 (en) 1994-12-29
NZ260842A (en) 1996-05-28
SI0633259T1 (en) 1999-06-30
LV11175A (lv) 1996-04-20
PL175771B1 (pl) 1999-02-26
JP2545200B2 (ja) 1996-10-16
LTIP1979A (en) 1995-01-31
ES2127850T3 (es) 1999-05-01
BR1100089A (pt) 2000-03-14
DK0633259T3 (da) 1999-09-06
CO4230230A1 (es) 1995-10-19
UA40578C2 (uk) 2001-08-15
GR3029874T3 (en) 1999-07-30
RO114325B1 (ro) 1999-03-30
BG61691B1 (bg) 1998-03-31
FI943084A0 (fi) 1994-06-27
SK77994A3 (en) 1995-03-08
IL110089A (en) 2000-08-31
HRP940370B1 (en) 1999-12-31
TW394761B (en) 2000-06-21

Similar Documents

Publication Publication Date Title
LV11175B (en) Novel sulfonylaminopyrymidine
DE69531457T2 (de) Sulfonamide
EP0601386B1 (de) Neue Sulfonamide
EP0510526B1 (de) Verwendung von Sulfonamiden als Heilmittel und neue Sulfonamide
AU676620B2 (en) Benzenesulfonamide derivative and process for preparing thereof
EP1601659B1 (de) Pyrimidin-2-on-verbindungen und ihre verwendung als dopamin-d3-rezeptorliganden
EP0526708B1 (de) Sulfonamide, ihre Herstellung und Verwendung als Heilmittel und Zwischenprodukte
AU2002351731A1 (en) Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
MXPA05011399A (es) Derivados de pirimidina utilies para el tratamiento de enfermedades mediadas por crth2.
AU2010224881A1 (en) Substituted pyrimidines for the treatment of cancer
EP0713875B1 (de) Neue Sulfonamide
CA2416785C (en) Novel arylethene-sulfonamides
EP0768304B1 (de) N-(Pyrimidinyl)-benzolsulfonamide als Arzneimittel
WO1999023078A2 (de) Neue carbonsäurederivate, die amidseitenketten tragen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
JP2790065B2 (ja) ベンゼンスルホンアミド誘導体及びその製法
JP3013752B2 (ja) スルホンアミド誘導体
JPH0959160A (ja) 医薬組成物
CA2389479A1 (en) Butyne diol derivatives
WO1996016963A1 (de) Sulfonamide und deren verwendung als heilmittel
DE69819774T2 (de) Verfahren zur herstellung von substituierten pyrimidinonen